We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.
OK
 

Key Financials

 

Consolidated Key Figures

(thousands of €, if not stated otherwise) Third quarter of 2019 Third quarter of 2018 Nine months ended 30 September 2019 Nine months ended 30 September 2018 Full year 2018
INCOME STATEMENT
Revenues 633,934 94,874 725,719 182,457 288,836
Other income 10,020 8,334 26,744 22,623 29,009
R&D expenditure (120,680) (80,314) (298,247) (231,758) (322,875)
S, G&A expenses (32,643) (10,623) (61,195) (26,837) (39,776)
Operating expenses (153,323) (90,937) (359,442) (258,595) (362,652)
Operating profit / loss (-) 490,631 12,271 393,021 (53,515) (44,807)
Net financial results (146,226) 2,091 (144,391) 8,958 15,598
Taxes 16,828 480 16,699 343 (50)
Net profit / net loss (-) 361,233 14,841 265,329 (44,215) (29,259)
 
BALANCE SHEET
Cash and cash equivalents 5,599,787 1,343,668 5,599,787 1,343,668 1,290,796
R&D incentives receivables 99,711 80,447 99,711 80,447 84,646
Assets (1) 5,851,752 1,485,551 5,851,752 1,485,551 1,439,496
Shareholders' equity (1) 2,535,281 1,188,222 2,535,281 1,188,222 1,214,249
Deferred income 3,127,777 209,742 3,127,777 209,742 149,801
Other liabilities (1) 188,695 87,587 188,695 87,587 75,446
 
CASH FLOW
Operational cash flow / burn (-) (2) 3,454,585 (5,571) 3,302,041 (100,581) (158,384)
Cash flow generated / used (-) in operating activities (1) 3,470,495 (3,640) 3,328,758 (94,918) (142,466)
Cash flow used in investing activities (14,221) (1,933) (22,881) (5,657) (15,914)
Cash flow generated in financing activities (1) 965,072 281,181 970,733 286,435 287,876
Increase in cash and cash equivalents 4,421,347 275,608 4,276,610 185,860 129,497
Effect of currency exchange rate fluctuation on cash and cash equivalents 30,514 1,292 32,380 6,596 10,089
Cash and cash equivalents at the end of the period 5,599,787 1,343,668 5,599,787 1,343,668 1,290,796
 
FINANCIAL RATIOS
Number of shares issued at the end of the period 61,953,831 54,299,136 61,953,831 54,299,136 54,465,421
Basic gain / loss (-) per share (in €) 6.26 0.29 4.77 (0.86) (0.56)
Diluted gain / loss (-) per share (in €) 6.03 0.28 4.59 (0.86) (0.56)
Total group employees at the end of the period (number) 918 712 918 712 725

(1) Our assets, shareholders’ equity, other liabilities, cash flow generated / used (–) in operating activities and cash flow generated in financing activities for the period ended 30 September 2019 were influenced by the adoption of the new standard IFRS 16 – Leases, on 1 January 2019. We refer to the notes of this condensed consolidated interim financial report for additional information.

(2) The operational cash burn (or operational cash flow if this performance measure is positive) is equal to the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
(i) the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated / used (–) in financing activities
(ii) the net proceeds or cash used, if any, in acquisitions or disposals of businesses; and the movement in restricted cash, if any, included in the net cash flows generated / used (–) in investing activities.
This alternative performance measure is in our view an important metric for a biotech company in the development stage.

Employees per site as of 30 September 2019 (total: 918 employees)

Employees September 2019